Journal article icon

Journal article

Human genetics of obesity and type 2 diabetes mellitus: past, present, and future

Abstract:
Type 2 diabetes mellitus (T2D) and obesity already represent 2 of the most prominent risk factors for cardiovascular disease, and are destined to increase in importance given the global changes in lifestyle. Ten years have passed since the first round of genome-wide association studies for T2D and obesity. During this decade, we have witnessed remarkable developments in human genetics. We have graduated from the despair of candidate gene-based studies that generated few consistently replicated genotype-phenotype associations, to the excitement of an exponential harvest of loci robustly associated with medical outcomes through ever larger genome-wide association study meta-analyses. As well as discovering hundreds of loci, genome-wide association studies have provided transformative insights into the genetic architecture of T2D and other complex traits, highlighting the extent of polygenicity and the tiny effect sizes of many common risk alleles. Genome-wide association studies have also provided a critical starting point for discovering new biology relevant to these traits. Expectations are high that these discoveries will foster development of more effective strategies for intervention, through optimization of precision medicine approaches. In this article, we review current knowledge and provide suggestions for the next steps in genetic research for T2D and obesity. We focus on four areas relevant to precision medicine: genetic architecture, pharmacogenetics and other gene-environment interactions, mechanistic inference, and drug development. As we describe, the genetic architecture of complex traits has major implications for the prospects of precision medicine, rendering some anticipated approaches decidedly unrealistic. We highlight obstacles to the translation of human genetic findings into mechanism inference but are optimistic that, as these are overcome, there is untapped potential for novel drugs and more effective strategies for treating and preventing T2D and obesity.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1161/CIRCGEN.118.002090

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Science Division
Department:
RDM; RDM Strategic
Oxford college:
Green Templeton College
Role:
Author
ORCID:
0000-0002-4393-0510


More from this funder
Funding agency for:
McCarthy, M
Grant:
U01DK105535
More from this funder
Funding agency for:
Ingelsson, E
Grant:
1R01HL135313-01
More from this funder
Funding agency for:
Ingelsson, E
McCarthy, M
Grant:
1R01HL135313-01
U01DK105535


Publisher:
American Heart Association
Journal:
Circulation: Genomic and Precision Medicine More from this journal
Volume:
11
Issue:
6
Article number:
e002090
Publication date:
2018-06-13
DOI:
ISSN:
2574-8300
Pmid:
29899044


Language:
English
Keywords:
Pubs id:
pubs:857280
UUID:
uuid:ec41fcde-75b7-4694-a2d1-a6398e0dbc3b
Local pid:
pubs:857280
Source identifiers:
857280
Deposit date:
2018-07-09

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP